|
|
 |
|
Viewing report
|
|
|
|
Winning R&D Productivity Strategies: Exploiting innovation, licensing and outsourcing opportunities
Business Insights, Oct 2006, Pages: 136
The need to produce novel drugs faster and more cheaply has put biopharma under intense pressure to innovate, despite rising costs and high risks. As R&D spend rises year on year, limited growth in the number of marketed drugs threatens to deepen the productivity crisis.
Our new report; Winning R&D Productivity Strategies provides in-depth analysis of current issues affecting R&D, with assessment of challenges to productivity including, rising costs of drug development, attrition rates and clinical development times. This report analyzes solutions already being implemented to boost productivity and how these are evolving. In addition, it outlines key best practices to improve productivity and reduce R&D costs.
Use this report to identify key areas of growth, effective strategies and innovative technologies to improve lead generation, attrition rates and return on investment from your portfolio.
Key questions answered
-India is forecast to be the most attractive country for outsourcing by 60% of industry executives.
-What is the current state of R&D in biopharma and what are the future challenges and opportunities for R&D?
-What are the most effective strategies to implement to address the rising costs of R&D and which companies have achieved this?
-How can innovative technologies, project and portfolio management and licensing and partnerships be implemented to reduce development times and improve the flow of drug candidates?
-What does the industry think of the future of R&D productivity and which strategies do they view as most attractive?
Key findings
-The largest share of the R&D spend by PhRMA members is in Phase III and prehuman/preclinical trials, and over 20% of drug failures in drug development have been attributed to toxicity concerns.
-Target validation is predicted to be the main focus of licensing deals by pharma in the next 3 years.
-The application of genomic technologies, such as biomarkers, offers the opportunity to save up to 34% of R&D costs.
-80% of industry executives believe that multi-product licensing deals are set to increase over the next 5 years.
-India is forecast to be the most attractive country for outsourcing by 60% of industry executives.
Hot issues covered in this report
-Licensing deals are increasing in complexity and value. The average value of deals have also increased over the last few years as indicated by $194m increase in average value of the top 10 pharmaceutical company licensing deals from 2001 to 2005.
-The move towards the networked pharma model. Biopharma are looking to exploit the flexible networked pharma model, which allows companies to gain benefits of a global scale pharma while keeping resources at a minimum and sharing risk.
-Emergence of innovative technologies. The vast range of technologies acts an opportunity to improve development times, attrition rates and end product price. The use of pharmacogenomics and biomarkers is set to rapidly increase and have a huge long term potential in drug discovery.
-Increased clinical development times. Development times have increased over the last decade, which is largely due to drugs becoming more innovative and subsequently requiring more testing and developing compared to less novel drugs with familiar mechanisms of action.
Top five reasons to order your copy today
-Identify strategies implemented by the biopharma industry to decrease R&D costs and increase productivity, and assess key trends and novel approaches to outsourcing and resource management which enable company re-structure and maximization of in-house resources.
-Assess key technology providers and establish which technologies should be implemented at various stages of the R&D process, enabling you to enhance productivity levels and gain a competitive edge.
-Benchmark your performance monitoring process, enabling you to choose the most appropriate markers to measure your own company productivity and assess your position within the industry.
-Develop innovative future strategies by utilizing the report’s analysis of successful project and portfolio, licensing and partnership and resource management strategies by companies including Wyeth, GlaxoSmithKline and AstraZeneca.
-Anticipate future trends in the market, by using the report’s predictions for areas of growth and gain insights into the outlook for innovative technologies in the R&D process.
Customers who bought this item also bought
Innovative Drug R&D in China
R&D Strategies: Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency
Bio/Pharma R&D Statistical Sourcebook 2008/2009
Innovative Strategies and Models for R&D Success: The Evolving Networked Pharma Company
Winning Pharmaceutical R&D Strategies: Boosting Profitability Through Improvements In Portfolio Management, Licensing And Clinical Trials
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Addressing Pharma’s R&D Productivity Crisis: Technological and Strategic Initiatives to Improve Core Drug Discovery Capabilities
Drug Repositioning Strategies: Innovative Strategies to Boost Pipeline Productivity
Licensing Strategies for Accessing Biomarker Technologies
Pharmaceutical R&D Statistical Sourcebook 2005/2006
Licensing in Antibacterial R&D - Filling the Gaps
|
|
|
|
